Stockwatch: When JnJ Speaks, Others Copy
This article was originally published in Scrip
Executive Summary
In David Thomas' 2011 novel Blood Relative, a husband tries to recreate his wife's life in the heart of the former German Democratic Republic as a time when the influence of the socialist state was absolute. In a similar way, but in the home of capitalism, the world's largest healthcare company Johnson & Johnson (J&J) reported its third-quarter earnings last week and its methods to massage the news quickly influenced announcements of much smaller companies.
You may also be interested in...
Stock Watch: Is Johnson & Johnson Edging Away From Pharma?
J&J’s Medtech division outshone pharma while recently launched innovative products contributed minimally: it is to be hoped investors’ reactions to the first set of big pharma Q1 results will not set the tempo for earnings season.
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.
Stock Watch: Pharma Businesses That Leave Consumer Behind
Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.